NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
11.62
+0.28 (2.47%)
At close: Aug 13, 2025, 4:00 PM
11.51
-0.11 (-0.95%)
Pre-market: Aug 14, 2025, 9:04 AM EDT
NovoCure Employees
NovoCure had 1,488 employees as of December 31, 2024. The number of employees increased by 35 or 2.41% compared to the previous year.
Employees
1,488
Change (1Y)
35
Growth (1Y)
2.41%
Revenue / Employee
$423,495
Profits / Employee
-$114,886
Market Cap
1.30B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NVCR News
- 15 days ago - NovoCure's Wearable Oncology Edge And Compelling Valuation - Seeking Alpha
- 17 days ago - Top 3 Health Care Stocks That May Explode In July - Benzinga
- 19 days ago - NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Novocure Reports Second Quarter 2025 Financial Results - Business Wire
- 6 weeks ago - Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025 - Business Wire
- 6 weeks ago - Novocure to Report Second Quarter 2025 Financial Results - Business Wire
- 2 months ago - NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial - Benzinga
- 2 months ago - Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Business Wire